• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Handling missing within-study correlations in the evaluation of surrogate endpoints.处理替代终点评估中研究内相关性缺失的问题。
Stat Med. 2023 Nov 20;42(26):4738-4762. doi: 10.1002/sim.9886. Epub 2023 Sep 3.
2
Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.比较贝叶斯分层元回归方法并评估先验信息对异质性临床试验集合中替代终点评估的影响。
BMC Med Res Methodol. 2024 Feb 16;24(1):39. doi: 10.1186/s12874-024-02170-0.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process.在药物研发过程中纳入多个替代终点的贝叶斯荟萃分析方法。
Stat Med. 2016 Mar 30;35(7):1063-89. doi: 10.1002/sim.6776. Epub 2015 Nov 3.
5
Accommodating missingness when assessing surrogacy via principal stratification.通过主要分层评估代孕时,考虑缺失数据。
Clin Trials. 2013;10(3):363-77. doi: 10.1177/1740774513479522. Epub 2013 Apr 3.
6
surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.surrosurv:用于在随机临床试验个体患者数据荟萃分析中评估失效时间替代终点的 R 包。
Comput Methods Programs Biomed. 2018 Mar;155:189-198. doi: 10.1016/j.cmpb.2017.12.005. Epub 2017 Dec 13.
7
How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.如何使用 frailtypack 验证来自随机对照试验荟萃分析的个体患者数据的失效时间替代终点。
PLoS One. 2020 Jan 28;15(1):e0228098. doi: 10.1371/journal.pone.0228098. eCollection 2020.
8
Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.正态分布替代终点的贝叶斯荟萃分析中的不确定性。
Stat Methods Med Res. 2017 Oct;26(5):2287-2318. doi: 10.1177/0962280215597260. Epub 2015 Aug 13.
9
Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.探索因果推断与荟萃分析范式在替代终点评估中的关系。
Stat Med. 2016 Apr 15;35(8):1281-98. doi: 10.1002/sim.6807. Epub 2015 Nov 26.
10
Bivariate network meta-analysis for surrogate endpoint evaluation.双变量网络荟萃分析用于替代终点评估。
Stat Med. 2019 Aug 15;38(18):3322-3341. doi: 10.1002/sim.8187. Epub 2019 May 26.

本文引用的文献

1
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.局部前列腺癌中替代终点的临床中期结果:汇总荟萃分析。
Lancet Oncol. 2021 Mar;22(3):402-410. doi: 10.1016/S1470-2045(20)30730-0.
2
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.评估美国食品药品监督管理局(FDA)替代终点表格中所包含的替代指标背后的证据,以支持癌症药物的批准。
EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr.
3
Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.用于使用汇总数据对跨治疗类别变化的替代关系进行建模的贝叶斯分层荟萃分析方法。
Stat Med. 2020 Apr 15;39(8):1103-1124. doi: 10.1002/sim.8465. Epub 2020 Jan 28.
4
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.白蛋白尿和肾小球滤过率(GFR)变化作为慢性肾脏病(CKD)早期临床试验的终点:美国国家肾脏基金会与美国食品和药物管理局(FDA)及欧洲药品管理局(EMA)合作举办的科学研讨会
Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28.
5
Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease.基于斜率的终点的混合效应模型在慢性肾脏病临床试验中的应用。
Stat Med. 2019 Sep 30;38(22):4218-4239. doi: 10.1002/sim.8282. Epub 2019 Jul 23.
6
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.GFR 斜率作为临床试验中肾脏疾病进展的替代终点:一项随机对照试验治疗效果的荟萃分析。
J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10.
7
Bivariate network meta-analysis for surrogate endpoint evaluation.双变量网络荟萃分析用于替代终点评估。
Stat Med. 2019 Aug 15;38(18):3322-3341. doi: 10.1002/sim.8187. Epub 2019 May 26.
8
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.白蛋白尿变化作为肾脏病进展的替代终点:随机临床试验治疗效果的荟萃分析。
Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.
9
Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.术前治疗的食管癌试验中无进展生存期(PFS)替代总生存期(OS):基于文献的荟萃分析
Eur J Surg Oncol. 2017 Oct;43(10):1956-1961. doi: 10.1016/j.ejso.2017.06.017. Epub 2017 Jul 15.
10
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.无进展生存期可作为人表皮生长因子受体 2 阳性转移性乳腺癌中曲妥珠单抗等 HER2 靶向药物临床试验的替代终点预测总生存期。
Ann Oncol. 2016 Jun;27(6):1029-1034. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8.

处理替代终点评估中研究内相关性缺失的问题。

Handling missing within-study correlations in the evaluation of surrogate endpoints.

机构信息

Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, USA.

出版信息

Stat Med. 2023 Nov 20;42(26):4738-4762. doi: 10.1002/sim.9886. Epub 2023 Sep 3.

DOI:10.1002/sim.9886
PMID:37845797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10704210/
Abstract

Rigorous evaluation of surrogate endpoints is performed in a trial-level analysis in which the strength of the association between treatment effects on the clinical and surrogate endpoints is quantified across a collection of previously conducted trials. To reduce bias in measures of the performance of the surrogate, the statistical model must account for the sampling error in each trial's estimated treatment effects and their potential correlation. Unfortunately, these within-study correlations can be difficult to obtain, especially for meta-analysis of published trial results where individual patient data is not available. As such, these terms are frequently partially or completely missing in the analysis. We show that improper handling of these missing terms can meaningfully alter the perceived quality of the surrogate and we introduce novel strategies to handle the missingness.

摘要

在试验层面的分析中,对替代终点进行严格评估,通过对一系列已开展试验的综合分析,量化治疗效果在临床终点和替代终点之间的关联强度。为了降低替代终点评估的偏倚,统计模型必须考虑到每个试验中估计的治疗效果的抽样误差及其潜在的相关性。不幸的是,这些研究内相关性很难获得,尤其是在分析已发表的试验结果的荟萃分析中,因为无法获得个体患者的数据。因此,在分析中这些术语经常部分或完全缺失。我们表明,对这些缺失术语的不当处理会显著改变对替代终点的质量的感知,我们引入了新的策略来处理缺失值。